Compare GH & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GH | BEN |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 14.5B |
| IPO Year | 2018 | 2013 |
| Metric | GH | BEN |
|---|---|---|
| Price | $78.81 | $24.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 9 |
| Target Price | ★ $120.05 | $25.89 |
| AVG Volume (30 Days) | 1.7M | ★ 4.5M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.27% |
| EPS Growth | 6.74 | ★ 7.06 |
| EPS | N/A | ★ 0.46 |
| Revenue | $982,021,000.00 | ★ $5,774,500,000.00 |
| Revenue This Year | $33.30 | N/A |
| Revenue Next Year | $28.19 | $5.76 |
| P/E Ratio | ★ N/A | $54.37 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $17.17 |
| 52 Week High | $120.74 | $28.32 |
| Indicator | GH | BEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 54.27 |
| Support Level | $54.39 | $24.12 |
| Resistance Level | $114.53 | $25.11 |
| Average True Range (ATR) | 5.45 | 0.67 |
| MACD | 0.07 | 0.27 |
| Stochastic Oscillator | 16.18 | 83.12 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.